Methodological education in response to the quality of COVID-19 publications.
作者信息
Andreotti Felicita, Gervasoni Cristina, Di Pasquale Giuseppe, Maggioni Aldo P
机构信息
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
出版信息
Pharmacol Res. 2021 Feb;164:105381. doi: 10.1016/j.phrs.2020.105381. Epub 2020 Dec 15.
Abstract
摘要
相似文献
1
Methodological education in response to the quality of COVID-19 publications.针对新冠疫情相关出版物质量的方法学教育
Pharmacol Res. 2021 Feb;164:105381. doi: 10.1016/j.phrs.2020.105381. Epub 2020 Dec 15.
2
Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities.早期新冠肺炎治疗临床试验的临床及方法学特征分析：工作量巨大，错失机遇众多。
BMC Med Res Methodol. 2021 Feb 26;21(1):42. doi: 10.1186/s12874-021-01233-w.
3
Scientific Rigor in the Age of COVID-19.新冠疫情时代的科学严谨性
JAMA Oncol. 2021 Feb 1;7(2):171-172. doi: 10.1001/jamaoncol.2020.6639.
4
Methodological challenges in studying the COVID-19 pandemic crisis.研究新冠疫情危机中的方法学挑战。
J Clin Epidemiol. 2020 May;121:A5-A7. doi: 10.1016/j.jclinepi.2020.04.001.
5
The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19.将直接病毒细胞病变假说应用于针对 COVID-19 的药物试验设计。
Daru. 2020 Dec;28(2):813-814. doi: 10.1007/s40199-020-00368-3. Epub 2020 Aug 15.
6
A call to arms.战斗的号召。
Science. 2021 Mar 12;371(6534):1092-1095. doi: 10.1126/science.371.6534.1092. Epub 2021 Mar 11.
7
The Landscape of Medical Literature in the Era of COVID-19: Original Research Versus Opinion Pieces.新冠疫情时代的医学文献格局：原创研究与观点文章
J Gen Intern Med. 2020 Sep;35(9):2813-2815. doi: 10.1007/s11606-020-06021-8. Epub 2020 Jul 8.
8
How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov.早期 SARS-CoV-2 治疗和预防试验有多大信息量？对 ClinicalTrials.gov 上注册的试验进行的纵向队列分析。
PLoS One. 2022 Jan 21;17(1):e0262114. doi: 10.1371/journal.pone.0262114. eCollection 2022.
9
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.严重急性呼吸综合征冠状病毒2：从发病机制到潜在的抗病毒治疗
Biomed Pharmacother. 2021 May;137:111352. doi: 10.1016/j.biopha.2021.111352. Epub 2021 Feb 2.
10
Waste in COVID-19 clinical trials conducted in western Europe.在西欧进行的新冠病毒疾病临床试验中的浪费现象。
Eur J Intern Med. 2020 Nov;81:91-93. doi: 10.1016/j.ejim.2020.07.002. Epub 2020 Jul 7.
引用本文的文献
1
The positive impact of COVID-19 on critical care: from unprecedented challenges to transformative changes, from the perspective of young intensivists.新冠疫情对重症监护的积极影响：从前所未有的挑战到变革性变化，以年轻重症医学专家的视角
Ann Intensive Care. 2023 Apr 11;13(1):28. doi: 10.1186/s13613-023-01118-9.
2
The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key?质子泵抑制剂在新冠病毒疾病中的难以捉摸的作用：血浆嗜铬粒蛋白A水平会是关键所在吗？
Pharmacol Res. 2023 Jan;187:106601. doi: 10.1016/j.phrs.2022.106601. Epub 2022 Dec 10.
本文引用的文献
1
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
2
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
3
Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19.在未经过筛选的新冠病毒疾病住院患者中，已确立的心血管生物标志物提供的预后信息有限。
Circulation. 2020 Nov 10;142(19):1878-1880. doi: 10.1161/CIRCULATIONAHA.120.050089. Epub 2020 Sep 10.
4
Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog.2019冠状病毒病研究的试验与磨难：雾中仍有几缕亮光
J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):841-844. doi: 10.2459/JCM.0000000000001099.
5
COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.意大利的 COVID-19 临床试验：呼吁简单化、高标准和全球资源共享。
Int J Cardiol. 2020 Nov 1;318:160-164. doi: 10.1016/j.ijcard.2020.06.043. Epub 2020 Jun 28.
6
[COVID-19 trials: surfing between expectations and illusions, looking forward to evidence].[新冠病毒疾病试验：在期望与幻想之间徘徊，期待证据]
G Ital Cardiol (Rome). 2020 Jul;21(7):479-482. doi: 10.1714/3386.33632.
7
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal.心房颤动合并急性冠状动脉综合征/经皮冠状动脉介入治疗中双联与三联抗栓治疗的随机试验和荟萃分析：一项批判性评估。
Int J Cardiol Heart Vasc. 2020 May 14;28:100524. doi: 10.1016/j.ijcha.2020.100524. eCollection 2020 Jun.
8
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
9
Key words to be adopted for COVID-19 research.用于COVID-19研究的关键词。
Eur Heart J. 2020 Nov 21;41(44):4229-4230. doi: 10.1093/eurheartj/ehaa322.
10
The Magic of Randomization versus the Myth of Real-World Evidence.随机化的魔力与真实世界证据的神话
N Engl J Med. 2020 Feb 13;382(7):674-678. doi: 10.1056/NEJMsb1901642.
Zotero 插件